Forma Therapeutics Holdings, Inc.

2021 Q1 Form 10-Q Financial Statement

#000156459021028009 Filed on May 14, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $550.7M $142.4M
YoY Change 286.73%
Cash & Equivalents $97.83M $110.3M
Short-Term Investments $452.9M $32.10M
Other Short-Term Assets $8.100M $3.300M
YoY Change 145.45%
Inventory
Prepaid Expenses $6.065M
Receivables $0.00
Other Receivables $30.90M
Total Short-Term Assets $573.9M $176.6M
YoY Change 224.97%
LONG-TERM ASSETS
Property, Plant & Equipment $1.420M $2.200M
YoY Change -35.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $53.00M
YoY Change
Other Assets $15.00M $13.50M
YoY Change 11.11%
Total Long-Term Assets $76.30M $15.80M
YoY Change 382.91%
TOTAL ASSETS
Total Short-Term Assets $573.9M $176.6M
Total Long-Term Assets $76.30M $15.80M
Total Assets $650.2M $192.4M
YoY Change 237.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.900M $2.000M
YoY Change 45.0%
Accrued Expenses $26.71M $19.20M
YoY Change 39.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.60M $21.90M
YoY Change 30.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.200M $1.700M
YoY Change 205.88%
Total Long-Term Liabilities $5.200M $1.700M
YoY Change 205.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.60M $21.90M
Total Long-Term Liabilities $5.200M $1.700M
Total Liabilities $33.80M $23.60M
YoY Change 43.22%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $616.5M $28.77M
YoY Change
Total Liabilities & Shareholders Equity $650.2M $192.4M
YoY Change 237.94%

Cashflow Statement

Concept 2021 Q1 2020 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9867000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8933000
CY2020Q1 us-gaap Restructuring Charges
RestructuringCharges
83000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
36210000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
32226000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-36210000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-32226000
CY2020Q1 fmtx Gain On Hit Discovery Divestiture
GainOnHitDiscoveryDivestiture
23312000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
262000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
641000
CY2021Q1 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-4000
CY2020Q1 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
18000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
258000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
23971000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35952000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8255000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-19485000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35960000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
11230000
CY2020Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-3456000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35960000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5838000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-35960000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3990000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1954000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-958000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
7754000
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.29
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.36
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47295013
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2548079
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47295013
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21392760
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
18246000
CY2020Q1 fmtx Accretion Of Cumulative Dividends On Redeemable Convertible Preferred Stock
AccretionOfCumulativeDividendsOnRedeemableConvertiblePreferredStock
1936000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2020Q1 fmtx Stock Issued During Period Value Exercise Of Warrants To Purchase Common Stock
StockIssuedDuringPeriodValueExerciseOfWarrantsToPurchaseCommonStock
12000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1210000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
28765000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
333000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3848000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
616465000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-35960000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
11230000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
183000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
543000
CY2021Q1 fmtx Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
375000
CY2021Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
3848000
CY2020Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1210000
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-20000
CY2021Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-377000
CY2020Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
27000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-227000
CY2021Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-207000
CY2020Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
19486000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1192000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2555000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1368000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1420000
CY2021Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
73000
CY2021Q1 fmtx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-473000
CY2020Q1 fmtx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-97000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41237000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33419000
CY2021Q1 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
257868000
CY2020Q1 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
32080000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
114500000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
83000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
78000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-143451000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29318000
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
333000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
CY2021Q1 fmtx Payment Of Public Offering Costs
PaymentOfPublicOfferingCosts
500000
CY2020Q1 fmtx Payment Of Public Offering Costs
PaymentOfPublicOfferingCosts
11000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-167000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-235000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-184855000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-62972000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
285159000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
173796000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100304000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110824000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
7478000
CY2020Q1 fmtx Accretion Of Preferred Return And Cumulative Dividends On Preferred Securities
AccretionOfPreferredReturnAndCumulativeDividendsOnPreferredSecurities
1936000
CY2020Q1 fmtx Deferred Offering Costs Included In Accounts Payable And Accrued Expenses And Other Current Liabilities
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
1025000
CY2020Q1 fmtx Installment Receivable In Prepaid Expenses And Other Current Assets
InstallmentReceivableInPrepaidExpensesAndOtherCurrentAssets
12710000
CY2020Q1 fmtx Equity Consideration In Other Assets
EquityConsiderationInOtherAssets
10000000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13148000
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13065000
CY2021Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2011-12-31
CY2020Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
160000000
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
45.25
CY2020Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
795000
CY2020Q4 fmtx Gross Proceeds From Follow On Public Offering
GrossProceedsFromFollowOnPublicOffering
275800000
CY2020Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
258600000
CY2021Q1 fmtx Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
603700000
CY2021Q1 fmtx Short Term Highly Liquid Investments With Original Maturities
ShortTermHighlyLiquidInvestmentsWithOriginalMaturities
90 days or less
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97834000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110329000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
2470000
CY2020Q1 us-gaap Restricted Cash
RestrictedCash
495000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
8900000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7478000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26705000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3025000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5879000
CY2021Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
600911000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
625392000
CY2020Q1 fmtx Accretion Of Cumulative Dividends Redeemable Convertible Preferred Shares
AccretionOfCumulativeDividendsRedeemableConvertiblePreferredShares
1.46
CY2021Q1 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
505890000
CY2021Q1 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
69000
CY2021Q1 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
40000
CY2021Q1 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
505919000
CY2020Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
362899000
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
38000
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
25000
CY2020Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
362912000
CY2021Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
191400000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
93700000
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6065000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4793000
CY2021Q1 us-gaap Other Receivables
OtherReceivables
2009000
CY2020Q4 us-gaap Other Receivables
OtherReceivables
1327000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8074000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11728000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11545000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1420000
CY2021Q1 fmtx Tenant Improvement Allowance
TenantImprovementAllowance
500000
CY2021Q1 us-gaap Other Assets
OtherAssets
500000
CY2021Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2024-01-31
CY2021Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The Arsenal Street Lease terms provide for one five-year extension term with base rent calculated on the then-market rate
CY2018Q1 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
1000000
CY2018Q1 fmtx Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2023-12
CY2018Q1 fmtx Unused Payments For Tenant Improvements
UnusedPaymentsForTenantImprovements
100000
CY2018Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease terms provide for one five-year extension term with base rent calculated on a discounted then-market rate.
CY2021Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000
CY2021Q1 us-gaap Sublease Income
SubleaseIncome
200000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
468000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
564000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2334000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3177000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
226000
CY2021Q1 us-gaap Lease Cost
LeaseCost
694000
CY2021Q1 fmtx Temporary Equity Shares Issued And Outstanding
TemporaryEquitySharesIssuedAndOutstanding
86062799
CY2021Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
140452000
CY2021Q1 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
136601000
CY2021Q1 fmtx Common Stock Issuable Upon Preferred Stock Conversion
CommonStockIssuableUponPreferredStockConversion
20349223000
CY2021Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10216606
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3848000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1210000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4941537
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1020795
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
68389
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
37517
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5856426
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3246000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
197000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8954000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
699000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
8255000
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M18D
CY2021Q1 fmtx Operating Lease Weighted Average Incremental Borrowing Rate Percent
OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent
0.060
CY2021Q1 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
2600000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3430000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6834000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
899000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1008000
CY2021Q1 fmtx Research And Development Expense Accruals
ResearchAndDevelopmentExpenseAccruals
17035000
CY2020Q4 fmtx Research And Development Expense Accruals
ResearchAndDevelopmentExpenseAccruals
18290000
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
851000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
972000
CY2021Q1 fmtx Accrued Expenses And Other Liabilities Current Net
AccruedExpensesAndOtherLiabilitiesCurrentNet
22215000
CY2020Q4 fmtx Accrued Expenses And Other Liabilities Current Net
AccruedExpensesAndOtherLiabilitiesCurrentNet
27104000
CY2021Q1 fmtx Cost For Guarantees And Indemnities
CostForGuaranteesAndIndemnities
0
CY2020Q4 fmtx Cost For Guarantees And Indemnities
CostForGuaranteesAndIndemnities
0
CY2019Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.40
CY2019Q1 us-gaap Restructuring Charges
RestructuringCharges
5400000
CY2021Q1 us-gaap Restructuring And Related Activities Description
RestructuringAndRelatedActivitiesDescription
The Company did not incur any charges in the first quarter of 2021 and the remaining balance of its restructuring accrual was paid in June 2020.
CY2019Q4 us-gaap Restructuring Reserve
RestructuringReserve
325000
CY2020Q1 us-gaap Severance Costs1
SeveranceCosts1
240000
CY2020Q1 us-gaap Restructuring Reserve
RestructuringReserve
168000
CY2020Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
20349223
CY2021Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
86362798
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1307293
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5856426
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.62
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
38.18
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.12
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.23
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.83
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.22
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
13.83
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y8M12D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y1M6D
CY2021Q1 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
2398000
CY2021Q1 fmtx Installment Receivable
InstallmentReceivable
12593000
CY2021Q1 fmtx Fair Value Of Consideration
FairValueOfConsideration
25554000
CY2021Q1 us-gaap Disposal Group Including Discontinued Operation Prepaid And Other Assets Current
DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
1117000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
130802000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
95441000
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
29803000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
95441000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0094
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0150
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.780
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.739
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q1 fmtx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price1
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice1
38.18
CY2020Q1 fmtx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price1
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice1
5.43
CY2021Q1 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
29700000
CY2020Q1 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
19500000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1239000
CY2021Q1 fmtx Contract With Customer Liability Current Deductions
ContractWithCustomerLiabilityCurrentDeductions
-1239000
CY2021Q1 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0
CY2020Q1 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0
CY2021Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2020Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2021Q1 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
17500000
CY2021Q1 fmtx Prepaid Of Reimbursement Expense
PrepaidOfReimbursementExpense
500000
CY2021Q1 fmtx Equity Consideration
EquityConsideration
10000000
CY2021Q1 fmtx Cash Due At Closing
CashDueAtClosing
2961000
CY2021Q1 us-gaap Disposal Group Including Discontinued Operation Other Noncurrent Assets
DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
125000
CY2021Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
3640000
CY2021Q1 us-gaap Disposal Group Including Discontinued Operation Accounts Payable
DisposalGroupIncludingDiscontinuedOperationAccountsPayable
159000
CY2021Q1 us-gaap Disposal Group Including Discontinued Operation Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationDeferredRevenue
1239000
CY2021Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
1398000
CY2021Q1 us-gaap Disposal Group Deferred Gain On Disposal
DisposalGroupDeferredGainOnDisposal
2242000
CY2021Q1 fmtx Impairment To Equity Consideration
ImpairmentToEquityConsideration
0

Files In Submission

Name View Source Status
0001564590-21-028009-index-headers.html Edgar Link pending
0001564590-21-028009-index.html Edgar Link pending
0001564590-21-028009.txt Edgar Link pending
0001564590-21-028009-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
fmtx-10q_20210331.htm Edgar Link pending
fmtx-20210331.xml Edgar Link completed
fmtx-20210331.xsd Edgar Link pending
fmtx-20210331_cal.xml Edgar Link unprocessable
fmtx-20210331_def.xml Edgar Link unprocessable
fmtx-20210331_lab.xml Edgar Link unprocessable
fmtx-20210331_pre.xml Edgar Link unprocessable
fmtx-ex311_7.htm Edgar Link pending
fmtx-ex312_6.htm Edgar Link pending
fmtx-ex321_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending